Evidence map›Paper›PMID 25282381›Full record

ReviewAlzheimer's & dementia : the journal of the Alzheimer's Association2015

Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research.

Sid E O'Bryant, Veer Gupta, Kim Henriksen, Melissa Edwards, Andreas Jeromin, Simone Lista, Chantal Bazenet, Holly Soares, Simon Lovestone, Harald Hampel and 19 more

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04265482 (GERO Cohort Protocol, Chile, 2017 - 2019), which is not on this map. Cited by 178 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
178citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04265482 unknown statusnot on this mapstarted 2017, after this paper: background citation

GERO Cohort Protocol, Chile, 2017 - 2019: Community-based Cohort of Functional Decline in Subjective Cognitive Complaint Elderly

TypeobservationalSponsorGeroscience Center for Brain Health and Metabolism (Gero)Ran2017 to 2023Enrolled300ConditionsSubjective Cognitive Complaint, Activities Daily Living, Dementia, Alzheimer Disease
3 · Its place in the literature

Who cites it

178 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Salivary AβJournal of neurology · 2023
    Pooled it
  4. Guidelines for the standardized collection of blood-based biomarkers in psychiatry: Steps for laboratory validity - a consensus of the Biomarkers Task Force from the WFSBP.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry · 2019
    Guideline
  5. Review
  6. Article
  7. Article
  8. Article
  9. Molecular and statistical weaknesses of the p-tau217/AβJournal of molecular medicine (Berlin, Germany) · 2026
    Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. "Advances in biomarker discovery and diagnostics for alzheimer's disease".Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Review

118 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Sid E O'BryantInstitute for Aging & Alzheimer's Disease Research and Department of Internal Medicine, University of North Texas Health Science Center, Fort Worth, TX, USA. Electronic address: sid.o'bryant@unthsc.edu.
Veer GuptaCentre of Excellence for Alzheimer's Disease Research & Care, School of Medical Sciences, Edith Cowan University, Joondalup, WA, Australia.
Kim HenriksenNordic Bioscience Biomarkers and Research, Neurodegenerative Diseases, Herlev, Denmark.
Melissa EdwardsDepartment of Psychology, University of North Texas, Denton, TX, USA.
Andreas JerominQuanterix, Inc., Lexington, MA, USA.
Simone ListaAXA Research Fund & UPMC Chair, Paris, France.
Chantal BazenetDepartment of Old Age Psychiatry, King's College London, Institute of Psychiatry, London, UK.
Holly SoaresBristol-Myers Squibb, Wallingford, CT, USA.
Simon LovestoneDepartment of Old Age Psychiatry, King's College London, Institute of Psychiatry, London, UK.
Harald HampelAXA Research Fund & UPMC Chair, Paris, France; Sorbonne Universités, Université Pierre et Marie Curie, Paris 06, Institut dela Mémoire et de la Maladie d'Alzheimer (IM2A) & Institut du Cerveau et dela Moelle épinière (ICM), Département de Neurologie, Hôpital de laPitié- Salpétrière, Paris, France; Département de Neurologie, Institut du Cerveau et de la Moelle épinière (ICM), Hôpital de la Pitié-Salpétrière, Paris, France.
Thomas MontineDepartment of Pathology, University of Washington, Seattle, WA, USA.
Kaj BlennowClinical Neurochemistry Laboratory, Department of Neuroscience and Physiology, University of Goteborg, Sahlgrenska University Hospital, Molndal, Sweden.
Tatiana ForoudDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA.
Maria CarrilloAlzheimer's Association, Chicago, IL, USA.
Neill Graff-RadfordDepartment of Neurology, Mayo Clinic Jacksonville, Jacksonville, FL, USA.
Christoph LaskeDepartment of Neurodegeneration, Center of Neurology, Section for Dementia Research, Hertie-Institute of Clinical Brain Research, University of Tubingen, Tubingen, Germany.
Monique BretelerDepartment of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany; German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
Leslie ShawDepartment of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany; German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
John Q TrojanowskiDepartment of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany; German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
Nicole SchupfDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Robert A RissmanDepartment of Epidemiology, Joseph P Mailman School of Public Health, Columbia University, New York, NY, USA.
Anne M FaganAlzheimer's Disease Cooperative Study, Department of Neurosciences, UCSD School of Medicine, La Jolla, CA, USA.
Pankaj OberoiDepartment of Neurology, Washington University School of Medicine, St. Louis, MO, USA.
Robert UmekMeso Scale Discovery, Rockville, MD, USA.
Michael W WeinerDepartment of Medicine, Radiology and Psychiatry, University of California, San Francisco, CA, USA.
Paula GrammasTexas Tech University Health Science Center, Garrison Institute on Aging, Lubbock, TX, USA.
Holly PosnerPfizer Inc., New York, NY, USA.
Ralph MartinsCentre of Excellence for Alzheimer's Disease Research & Care, School of Medical Sciences, Edith Cowan University, Joondalup, WA, Australia.
STAR-B and BBBIG working groups

Funding

THERAPEUTIC EFFECTS OF INTRA-NASAL INSULIN DETEMIRP50AG005136 · NIA · UNIVERSITY OF WASHINGTON · PI JAYADEY, SUMAN · 1985 to 2019
$57.2M
The natural history of AB accumulation in preclinical ADP01AG026276 · NIA · WASHINGTON UNIVERSITY · PI SCHINDLER, SUZANNE ELIZABETH · 2005 to 2025
$49.5M
UPenn ADCC Biomarker CoreP30AG010124 · NIA · UNIVERSITY OF PENNSYLVANIA · PI XIE, SHARON XIANGWEN · 1991 to 2020
$35.1M
ROLE OF GLUTAMATE IN ALZHEIMER'S DISEASEP30AG012300 · NIA · UT SOUTHWESTERN MEDICAL CENTER · PI ROSENBERG, ROGER NEWMAN · 1994 to 2016
$26.6M
A Blood-Based Screening Tool for Alzheimer's DiseaseR01AG039389 · NIA · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI O'BRYANT, SID E · 2012 to 2013
$608k
Department of Health NF-SI-0512-10053Medical Research Council G0801464NIA NIH HHS P01 AG026276NIA NIH HHS P30 AG010124NIA NIH HHS P30 AG012300NIA NIH HHS P30AG12300NIA NIH HHS P50 AG005136NIA NIH HHS P50AG05136NIA NIH HHS R01 AG039389NIA NIH HHS R01AG039389
6 · The paper itself

Abstract

The lack of readily available biomarkers is a significant hindrance toward progressing to effective therapeutic and preventative strategies for Alzheimer's disease (AD). Blood-based biomarkers have potential to overcome access and cost barriers and greatly facilitate advanced neuroimaging and cerebrospinal fluid biomarker approaches. Despite the fact that preanalytical processing is the largest source of variability in laboratory testing, there are no currently available standardized preanalytical guidelines. The current international working group provides the initial starting point for such guidelines for standardized operating procedures (SOPs). It is anticipated that these guidelines will be updated as additional research findings become available. The statement provides (1) a synopsis of selected preanalytical methods utilized in many international AD cohort studies, (2) initial draft guidelines/SOPs for preanalytical methods, and (3) a list of required methodological information and protocols to be made available for publications in the field to foster cross-validation across cohorts and laboratories.

Indexed as

Alzheimer DiseaseBiomarkersGuidelines as TopicHumansBiomarkersAlzheimer's diseaseBiomarkersBloodDementiaDiagnosisPlasmaSerumTreatment

Identifiers

PMID25282381
PMCPMC4414664

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.